{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T14:56:21Z","timestamp":1782226581281,"version":"3.54.5"},"reference-count":168,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T00:00:00Z","timestamp":1700524800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016566","name":"Mohammed VI Polytechnic University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016566","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016150","name":"OCP Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015666","name":"Aksum University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015666","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes & Diseases"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.gendis.2023.101174","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T02:57:01Z","timestamp":1700708221000},"page":"101174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2803-5024","authenticated-orcid":false,"given":"Abdellatif","family":"El Khayari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7074-1750","authenticated-orcid":false,"given":"Soukaina Miya","family":"Hakam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Malka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Rochette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7652-5562","authenticated-orcid":false,"given":"Rachid","family":"El Fatimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gendis.2023.101174_bib1","series-title":"StatPearls","article-title":"Diabetes mellitus type 2","author":"Goyal","year":"2022"},{"issue":"2","key":"10.1016\/j.gendis.2023.101174_bib2","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/diabetology2020004","article-title":"Diabetes mellitus: insights from epidemiology, biochemistry, risk factors, diagnosis, complications and comprehensive management","volume":"2","author":"Alam","year":"2021","journal-title":"Diabetology"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5001\/omj.2012.68","article-title":"Type 2 diabetes mellitus: a review of current trends","volume":"27","author":"Olokoba","year":"2012","journal-title":"Oman Med J"},{"key":"10.1016\/j.gendis.2023.101174_bib4","series-title":"Global Report on Diabetes","author":"World Health Organization","year":"2016"},{"issue":"2","key":"10.1016\/j.gendis.2023.101174_bib5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41574-020-00453-2","article-title":"SGLT2 inhibitors in people with and without T2DM","volume":"17","author":"Khunti","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"9","key":"10.1016\/j.gendis.2023.101174_bib6","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.015716","volume":"9","author":"Ikonomidis","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib7","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.gendis.2023.101174_bib8","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.gendis.2023.101174_bib9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.gendis.2023.101174_bib10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.gendis.2023.101174_bib11","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.gendis.2023.101174_bib12","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/CIRCULATIONAHA.107.687947","article-title":"microRNAs in the human heart: a clue to fetal gene reprogramming in heart failure","volume":"116","author":"Thum","year":"2007","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.gendis.2023.101174_bib14","doi-asserted-by":"crossref","first-page":"865","DOI":"10.17219\/acem\/62915","article-title":"microRNA in cardiovascular biology and disease","volume":"26","author":"Wojciechowska","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"10.1016\/j.gendis.2023.101174_bib15","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9623412","article-title":"miR-30 family: a promising regulator in development and disease","volume":"2018","author":"Mao","year":"2018","journal-title":"Biomed Res Int"},{"issue":"8","key":"10.1016\/j.gendis.2023.101174_bib16","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20190788","article-title":"The microRNA in ventricular remodeling: the miR-30 family","volume":"39","author":"Zhang","year":"2019","journal-title":"Biosci Rep"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib17","doi-asserted-by":"crossref","first-page":"10900","DOI":"10.1038\/s41598-019-47504-x","article-title":"Differential expression of urinary exosomal microRNAs miR-21-5p and miR-30b-5p in individuals with diabetic kidney disease","volume":"9","author":"Zang","year":"2019","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317692204","article-title":"The miR-30 family: versatile players in breast cancer","volume":"39","author":"Yang","year":"2017","journal-title":"Tumour Biol"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.tig.2018.12.005","article-title":"miRNA targeting: growing beyond the seed","volume":"35","author":"Chipman","year":"2019","journal-title":"Trends Genet"},{"issue":"10","key":"10.1016\/j.gendis.2023.101174_bib20","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits","volume":"61","author":"Lupsa","year":"2018","journal-title":"Diabetologia"},{"issue":"12","key":"10.1016\/j.gendis.2023.101174_bib21","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.gendis.2023.101174_bib23","series-title":"Guidelines on Second- and Third-Line Medicines and Type of Insulin for the Control of Blood Glucose Levels in Non-pregnant Adults with Diabetes Mellitus","year":"2018"},{"key":"10.1016\/j.gendis.2023.101174_bib24","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.2147\/DDDT.S114932","article-title":"Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date","volume":"11","author":"Cinti","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"11","key":"10.1016\/j.gendis.2023.101174_bib25","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1111\/dom.14127","article-title":"Sotagliflozin added to optimized insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2","volume":"22","author":"Rodbard","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.gendis.2023.101174_bib26","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes","volume":"38","author":"Sands","year":"2015","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.gendis.2023.101174_bib27","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2337\/dc18-0343","article-title":"Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study","volume":"41","author":"Buse","year":"2018","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1016\/j.gendis.2023.101174_bib28","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib29","doi-asserted-by":"crossref","first-page":"dgz258","DOI":"10.1210\/clinem\/dgz258","article-title":"Sotagliflozin decreases postprandial glucose and insulin concentrations by delaying intestinal glucose absorption","volume":"105","author":"Powell","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.gendis.2023.101174_bib30","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2337\/dc18-0342","article-title":"HbA1c and hypoglycemia reductions at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study","volume":"41","author":"Danne","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"5","key":"10.1016\/j.gendis.2023.101174_bib32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41581-021-00393-8","article-title":"Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors","volume":"17","author":"DeFronzo","year":"2021","journal-title":"Nat Rev Nephrol"},{"issue":"9","key":"10.1016\/j.gendis.2023.101174_bib33","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis","volume":"5","author":"Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib34","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/1753-0407.12524","article-title":"American diabetes association standards of medical care in diabetes 2017","volume":"9","author":"Marathe","year":"2017","journal-title":"J Diabetes"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.diabet.2019.01.008","article-title":"Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications","volume":"45","author":"Scheen","year":"2019","journal-title":"Diabetes Metab"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib36","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3892\/etm.2021.9813","article-title":"Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a meta-analysis of randomized controlled trials","volume":"21","author":"Huang","year":"2021","journal-title":"Exp Ther Med"},{"issue":"12","key":"10.1016\/j.gendis.2023.101174_bib37","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrendo.2017.139","article-title":"Therapy: SGLT inhibition in T1DM - definite benefit with manageable risk","volume":"13","author":"Ferrannini","year":"2017","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.1016\/j.gendis.2023.101174_bib38","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41591-022-01805-3","article-title":"Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2 \u00d7 2 factorial randomized crossover trial","volume":"28","author":"Haidar","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.gendis.2023.101174_bib39","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.2147\/DMSO.S194688","article-title":"Empagliflozin in type 1 diabetes","volume":"12","author":"Mathieu","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"10","key":"10.1016\/j.gendis.2023.101174_bib40","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1007\/s00125-018-4671-6","article-title":"SGLT inhibitor adjunct therapy in type 1 diabetes","volume":"61","author":"McCrimmon","year":"2018","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/j.gendis.2023.101174_bib41","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.gendis.2023.101174_bib42","doi-asserted-by":"crossref","first-page":"1145587","DOI":"10.3389\/fphar.2023.1145587","article-title":"Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials","volume":"14","author":"Yang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gendis.2023.101174_bib43","unstructured":"Australian Diabetes Society. Diabetic ketoacidosis (DKA) with SGLT2 inhibitor use. Part Perioper. Available at: https:\/\/diabetessociety.com.au\/documents\/August2019_ALERT-ADS_ SGLT2i_PerioperativeKetoacidosisfinal.pdf."},{"key":"10.1016\/j.gendis.2023.101174_bib44","doi-asserted-by":"crossref","DOI":"10.1177\/2042018819890527","article-title":"A review of sotagliflozin for use in type 1 diabetes","volume":"10","author":"Nuffer","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.gendis.2023.101174_bib45","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(19)30154-8","article-title":"SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks","volume":"7","author":"Taylor","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"22","key":"10.1016\/j.gendis.2023.101174_bib46","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1161\/CIRCULATIONAHA.120.053463","article-title":"Metabolic effects of empagliflozin in heart failure: a randomized, double-blind, and placebo-controlled trial (empire HF metabolic)","volume":"143","author":"Jensen","year":"2021","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.gendis.2023.101174_bib47","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib48","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/EJE-17-0832","article-title":"Mechanisms in endocrinology: SGLT2 inhibitors: clinical benefits by restoration of normal diurnal metabolism?","volume":"178","author":"Esterline","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.gendis.2023.101174_bib49","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.jchf.2021.04.014","article-title":"Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study","volume":"9","author":"Requena-Ib\u00e1\u00f1ez","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"9","key":"10.1016\/j.gendis.2023.101174_bib50","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1161\/ATVBAHA.118.311339","article-title":"Mechanism of increased LDL (low-density lipoprotein) and decreased triglycerides with SGLT2 (sodium-glucose cotransporter 2) inhibition","volume":"38","author":"Basu","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"10.1016\/j.gendis.2023.101174_bib51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/metabo11020087","article-title":"The effects of SGLT2 inhibitors on lipid metabolism","volume":"11","author":"Szekeres","year":"2021","journal-title":"Metabolites"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib52","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dci19-0074","article-title":"SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action","volume":"43","author":"Packer","year":"2020","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.gendis.2023.101174_bib53","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123130","article-title":"SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms","volume":"4","author":"Osataphan","year":"2019","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.gendis.2023.101174_bib54","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"15","key":"10.1016\/j.gendis.2023.101174_bib55","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/j.jacc.2019.02.023","article-title":"SGLT2 inhibition: changing what fuels the heart","volume":"73","author":"Lehrke","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.gendis.2023.101174_bib56","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1007\/s00125-018-4669-0","article-title":"The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure","volume":"61","author":"Thomas","year":"2018","journal-title":"Diabetologia"},{"issue":"15","key":"10.1016\/j.gendis.2023.101174_bib57","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.gendis.2023.101174_bib58","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.122.060805","article-title":"SGLT2 inhibitors in heart failure: targeted metabolomics and energetic metabolism","volume":"146","author":"Santos-Gallego","year":"2022","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib59","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cmet.2014.07.012","article-title":"FGF21 acts centrally to induce sympathetic nerve activity, energy expenditure, and weight loss","volume":"20","author":"Owen","year":"2014","journal-title":"Cell Metab"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib60","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12933-019-0852-y","article-title":"Effect of SGLT2 inhibitors on body composition, fluid status and renin-angiotensin-aldosterone system in type 2 diabetes: a prospective study using bioimpedance spectroscopy","volume":"18","author":"Schork","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib61","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2337\/dc19-1410","article-title":"Reinterpreting cardiorenal protection of renal sodium-glucose cotransporter 2 inhibitors via cellular life history programming","volume":"43","author":"Avogaro","year":"2020","journal-title":"Diabetes Care"},{"issue":"17","key":"10.1016\/j.gendis.2023.101174_bib62","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1161\/CIR.0000000000000920","volume":"142","author":"Rangaswami","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.gendis.2023.101174_bib63","doi-asserted-by":"crossref","first-page":"154918","DOI":"10.1016\/j.metabol.2021.154918","article-title":"Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease","volume":"126","author":"Liu","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.gendis.2023.101174_bib64","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-023-07469-6","article-title":"Rationale and design of the SOTA-P-CARDIA trial (ATRU-V): sotagliflozin in HFpEF patients without diabetes","author":"P\u00e9rez","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.gendis.2023.101174_bib65","article-title":"Sotagliflozin: an insight into the first dual SGLT inhibitor now approved for heart failure","volume":"193","author":"Affan","year":"2023","journal-title":"Ir J Med Sci"},{"issue":"2","key":"10.1016\/j.gendis.2023.101174_bib66","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.gendis.2023.101174_bib67","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.gendis.2023.101174_bib68","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.gendis.2023.101174_bib69","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"10.1016\/j.gendis.2023.101174_bib70","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib71","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/HYPERTENSIONAHA.119.11684","article-title":"Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors","volume":"75","author":"Wilcox","year":"2020","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib72","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors","volume":"75","author":"Zelniker","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.gendis.2023.101174_bib73","doi-asserted-by":"crossref","DOI":"10.1177\/1753944720939383","article-title":"Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation","volume":"14","author":"Sano","year":"2020","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"6","key":"10.1016\/j.gendis.2023.101174_bib74","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/cvr\/cvz302","article-title":"Systematic review of microRNA biomarkers in acute coronary syndrome and stable coronary artery disease","volume":"116","author":"Kaur","year":"2020","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib75","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1159\/000459899","article-title":"Circulating miR-30d predicts survival in patients with acute heart failure","volume":"41","author":"Xiao","year":"2017","journal-title":"Cell Physiol Biochem"},{"issue":"10","key":"10.1016\/j.gendis.2023.101174_bib76","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/eurjhf\/hft078","article-title":"Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients","volume":"15","author":"Ellis","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"7","key":"10.1016\/j.gendis.2023.101174_bib77","doi-asserted-by":"crossref","first-page":"144","DOI":"10.21037\/atm.2016.03.12","article-title":"My heart will go on-beneficial effects of anti-MiR-30 after myocardial infarction","volume":"4","author":"Li","year":"2016","journal-title":"Ann Transl Med"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib78","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1089\/ars.2014.5909","article-title":"miRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-\u03b3-lyase expression","volume":"22","author":"Shen","year":"2015","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"10.1016\/j.gendis.2023.101174_bib79","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3109\/10641963.2016.1163370","article-title":"Circulating miR-30 is related to carotid artery atherosclerosis","volume":"38","author":"Huang","year":"2016","journal-title":"Clin Exp Hypertens"},{"issue":"12","key":"10.1016\/j.gendis.2023.101174_bib80","first-page":"15527","article-title":"miR-30a regulates the atrial fibrillation-induced myocardial fibrosis by targeting snail 1","volume":"8","author":"Yuan","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"issue":"2","key":"10.1016\/j.gendis.2023.101174_bib81","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1161\/CIRCRESAHA.108.182535","article-title":"miR-133 and miR-30 regulate connective tissue growth factor","volume":"104","author":"Duisters","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.gendis.2023.101174_bib82","doi-asserted-by":"crossref","first-page":"186","DOI":"10.3389\/fgene.2014.00186","article-title":"Desregulated microRNAs in aging-related heart failure","volume":"5","author":"Zhuo","year":"2014","journal-title":"Front Genet"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib83","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIRCRESAHA.120.317244","article-title":"miR-30d regulates cardiac remodeling by intracellular and paracrine signaling","volume":"128","author":"Li","year":"2021","journal-title":"Circ Res"},{"issue":"5","key":"10.1016\/j.gendis.2023.101174_bib84","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.89","article-title":"Myocardial miR-30 downregulation triggered by doxorubicin drives alterations in \u03b2-adrenergic signaling and enhances apoptosis","volume":"6","author":"Roca-Alonso","year":"2015","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.gendis.2023.101174_bib85","doi-asserted-by":"crossref","DOI":"10.1177\/1536012119894087","article-title":"The relationship between IDH1 mutation status and metabolic imaging in nonenhancing supratentorial diffuse gliomas: a 11C-MET PET study","volume":"18","author":"Kudulaiti","year":"2019","journal-title":"Mol Imaging"},{"key":"10.1016\/j.gendis.2023.101174_bib86","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ijcard.2016.11.279","article-title":"Relations between circulating microRNAs (miR-21, miR-26, miR-29, miR-30 and miR-133a), extracellular matrix fibrosis and serum markers of fibrosis in dilated cardiomyopathy","volume":"231","author":"Rubi\u015b","year":"2017","journal-title":"Int J Cardiol"},{"issue":"6","key":"10.1016\/j.gendis.2023.101174_bib87","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1253\/circj.CJ-15-1276","article-title":"Atrial fibrillation-mediated upregulation of miR-30d regulates myocardial electrical remodeling of the G-protein-gated K+ channel, IK.ACh","volume":"80","author":"Morishima","year":"2016","journal-title":"Circ J"},{"issue":"6","key":"10.1016\/j.gendis.2023.101174_bib88","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/ejhf.1119","article-title":"Transcoronary concentration gradients of circulating microRNAs in heart failure","volume":"20","author":"De Rosa","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.gendis.2023.101174_bib89","doi-asserted-by":"crossref","first-page":"9883","DOI":"10.1038\/s41598-018-28118-1","article-title":"Circulating miR-30a-5p as a prognostic biomarker of left ventricular dysfunction after acute myocardial infarction","volume":"8","author":"Maciejak","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053950","article-title":"miR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy","volume":"8","author":"Pan","year":"2013","journal-title":"PLoS One"},{"issue":"25","key":"10.1016\/j.gendis.2023.101174_bib91","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.114.013220","article-title":"Circulating microRNA-30d is associated with response to cardiac resynchronization therapy in heart failure and regulates cardiomyocyte apoptosis: a translational pilot study","volume":"131","author":"Melman","year":"2015","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.gendis.2023.101174_bib92","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/eurjhf\/hft088","article-title":"Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders","volume":"15","author":"Marfella","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib93","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1681\/ASN.2012111101","article-title":"Downregulation of microRNA-30 facilitates podocyte injury and is prevented by glucocorticoids","volume":"25","author":"Wu","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.gendis.2023.101174_bib94","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3389\/fgene.2019.00563","article-title":"miR-30e-5p and miR-15a-5p expressions in plasma and urine of type 1 diabetic patients with diabetic kidney disease","volume":"10","author":"Dieter","year":"2019","journal-title":"Front Genet"},{"issue":"10","key":"10.1016\/j.gendis.2023.101174_bib95","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41581-022-00608-6","article-title":"microRNAs in kidney injury and disease","volume":"18","author":"Mahtal","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"11","key":"10.1016\/j.gendis.2023.101174_bib96","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1681\/ASN.2008030312","article-title":"Podocyte-selective deletion of dicer induces proteinuria and glomerulosclerosis","volume":"19","author":"Shi","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1016\/j.gendis.2023.101174_bib97","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/iub.1174","article-title":"The regulation and function of microRNAs in kidney diseases","volume":"65","author":"Wei","year":"2013","journal-title":"IUBMB Life"},{"issue":"5","key":"10.1016\/j.gendis.2023.101174_bib98","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1681\/ASN.2009070718","article-title":"Targeted deletion of Dicer from proximal tubules protects against renal ischemia-reperfusion injury","volume":"21","author":"Wei","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.gendis.2023.101174_bib99","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3109\/0886022X.2015.1077322","article-title":"Dysregulated microRNAs involved in contrast-induced acute kidney injury in rat and human","volume":"37","author":"Guti\u00e9rrez-Escolano","year":"2015","journal-title":"Ren Fail"},{"issue":"8","key":"10.1016\/j.gendis.2023.101174_bib100","doi-asserted-by":"crossref","first-page":"e2987","DOI":"10.1038\/cddis.2017.377","article-title":"miR-30c regulates cisplatin-induced apoptosis of renal tubular epithelial cells by targeting Bnip3L and Hspa5","volume":"8","author":"Du","year":"2017","journal-title":"Cell Death Dis"},{"issue":"8","key":"10.1016\/j.gendis.2023.101174_bib101","first-page":"5517","article-title":"miR-30c inhibits renal fibrosis in diabetic nephropathy by down-regulating ROCK2","volume":"13","author":"Yuan","year":"2020","journal-title":"Int J Clin Exp Med"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib102","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1152\/physiolgenomics.00039.2017","article-title":"Therapeutic potential of microRNAs for the treatment of renal fibrosis and CKD","volume":"50","author":"Lv","year":"2018","journal-title":"Physiol Genom"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib103","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.bbrc.2011.12.121","article-title":"miR-30 inhibits TGF-\u03b21-induced epithelial-to-mesenchymal transition in hepatocyte by targeting Snail1","volume":"417","author":"Zhang","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib104","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00109-015-1340-9","article-title":"TGF-\u03b2 induces miR-30d down-regulation and podocyte injury through Smad2\/3 and HDAC3-associated transcriptional repression","volume":"94","author":"Liu","year":"2016","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.gendis.2023.101174_bib105","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fphar.2017.00461","article-title":"Targeting TGF-\u03b2 mediated SMAD signaling for the prevention of fibrosis","volume":"8","author":"Walton","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.gendis.2023.101174_bib106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coph.2018.11.002","article-title":"Impact of currently used anti-diabetic drugs on myoendothelial communication","volume":"45","author":"Ding","year":"2019","journal-title":"Curr Opin Pharmacol"},{"issue":"11","key":"10.1016\/j.gendis.2023.101174_bib107","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.3390\/ijms22116044","article-title":"Sodium glucose co-transporter 2 inhibitors ameliorate endothelium barrier dysfunction induced by cyclic stretch through inhibition of reactive oxygen species","volume":"22","author":"Li","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.gendis.2023.101174_bib108","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s13300-020-00885-z","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on endothelial function: a systematic review of preclinical studies","volume":"11","author":"Alshnbari","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.gendis.2023.101174_bib109","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.yjmcc.2015.10.009","article-title":"microRNA-30 mediates anti-inflammatory effects of shear stress and KLF2 via repression of angiopoietin 2","volume":"88","author":"Demolli","year":"2015","journal-title":"J Mol Cell Cardiol"},{"issue":"2","key":"10.1016\/j.gendis.2023.101174_bib110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nm1351","article-title":"Angiopoietin-2 sensitizes endothelial cells to TNF-\u03b1 and has a crucial role in the induction of inflammation","volume":"12","author":"Fiedler","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.gendis.2023.101174_bib111","article-title":"The miR-30 family is regulated by shear stress and affects the expression of inflammatory cell-cell adhesion molecules","volume":"124","author":"Doebele","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.gendis.2023.101174_bib112","doi-asserted-by":"crossref","first-page":"1342190","DOI":"10.1155\/2019\/1342190","article-title":"microRNA-30-3p suppresses inflammatory factor-induced endothelial cell injury by targeting TCF21","volume":"2019","author":"Zhou","year":"2019","journal-title":"Mediators Inflamm"},{"issue":"2","key":"10.1016\/j.gendis.2023.101174_bib113","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1080\/21655979.2021.2019878","article-title":"Knockdown of long non-coding RNA plasmacytoma variant translocation 1 relieves ox-LDL-induced endothelial cell injury through regulating microRNA-30c-5p in atherosclerosis","volume":"13","author":"Li","year":"2022","journal-title":"Bioengineered"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib114","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1159\/000430402","article-title":"Endothelial cell autophagy in atherosclerosis is regulated by miR-30-mediated translational control of ATG6","volume":"37","author":"Zhang","year":"2015","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib115","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1002\/jcb.27708","article-title":"Endothelial cell autophagy in chronic intermittent hypoxia is impaired by miRNA-30a-mediated translational control of Beclin-1","volume":"120","author":"Bi","year":"2019","journal-title":"J Cell Biochem"},{"issue":"6","key":"10.1016\/j.gendis.2023.101174_bib116","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317703984","article-title":"miR-30d suppresses cell proliferation of colon cancer cells by inhibiting cell autophagy and promoting cell apoptosis","volume":"39","author":"Zhang","year":"2017","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib117","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/09168451.2016.1238294","article-title":"miR-30 functions as an oncomiR in gastric cancer cells through regulation of P53-mediated mitochondrial apoptotic pathway","volume":"81","author":"Wang","year":"2017","journal-title":"Biosci Biotechnol Biochem"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib118","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1253\/circj.CJ-16-0751","article-title":"Effect of microRNA-30e on the behavior of vascular smooth muscle cells via targeting ubiquitin-conjugating enzyme E2I","volume":"81","author":"Zong","year":"2017","journal-title":"Circ J"},{"issue":"7","key":"10.1016\/j.gendis.2023.101174_bib119","doi-asserted-by":"crossref","first-page":"9348","DOI":"10.18632\/aging.202719","article-title":"miR-30c-1 encourages human corneal endothelial cells to regenerate through ameliorating senescence","volume":"13","author":"Bae","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.gendis.2023.101174_bib120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3389\/fcvm.2016.00043","article-title":"Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse","volume":"3","author":"Salim","year":"2016","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.gendis.2023.101174_bib121","doi-asserted-by":"crossref","first-page":"174715","DOI":"10.1016\/j.ejphar.2021.174715","article-title":"Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-\u03baB activation in human endothelial cells and differentiated macrophages","volume":"918","author":"Abdollahi","year":"2022","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.gendis.2023.101174_bib122","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1\u03b2-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and-independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib123","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","article-title":"Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice","volume":"17","author":"Nasiri-Ansari","year":"2018","journal-title":"Cardiovasc Diabetol"},{"issue":"8","key":"10.1016\/j.gendis.2023.101174_bib124","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/ATVBAHA.119.312659","article-title":"SGLT-2 (sodium-glucose cotransporter 2) inhibition reduces ang II (angiotensin II)-induced dissecting abdominal aortic aneurysm in ApoE (apolipoprotein E) knockout mice","volume":"39","author":"Ortega","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib125","doi-asserted-by":"crossref","first-page":"18384","DOI":"10.1038\/s41598-021-97787-2","article-title":"Empagliflozin maintains capillarization and improves cardiac function in a murine model of left ventricular pressure overload","volume":"11","author":"Nakao","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.gendis.2023.101174_bib126","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor \u03b1-stimulated human coronary arterial endothelial cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell Physiol Biochem"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib127","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11010-007-9669-1","article-title":"Na+\/H+ exchange inhibition with cariporide prevents alterations of coronary endothelial function in streptozotocin-induced diabetes","volume":"310","author":"Vial","year":"2008","journal-title":"Mol Cell Biochem"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib128","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.123.015298","article-title":"Cardioprotective effect of empagliflozin and circulating ketone bodies during acute myocardial infarction","volume":"16","author":"Santos-Gallego","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.gendis.2023.101174_bib129","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4239\/wjd.v12.i2.124","article-title":"Role of ferroptosis in the process of diabetes-induced endothelial dysfunction","volume":"12","author":"Luo","year":"2021","journal-title":"World J Diabetes"},{"issue":"8","key":"10.1016\/j.gendis.2023.101174_bib130","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00210-022-02243-1","article-title":"Canagliflozin mitigates ferroptosis and ameliorates heart failure in rats with preserved ejection fraction","volume":"395","author":"Ma","year":"2022","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib131","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.gendis.2023.101174_bib132","doi-asserted-by":"crossref","first-page":"112421","DOI":"10.1016\/j.biopha.2021.112421","article-title":"Emerging role of long non-coding RNAs in endothelial dysfunction and their molecular mechanisms","volume":"145","author":"Jayasuriya","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"10.1016\/j.gendis.2023.101174_bib133","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11906-016-0696-8","article-title":"Role of microRNA in endothelial dysfunction and hypertension","volume":"18","author":"Nemecz","year":"2016","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.gendis.2023.101174_bib134","doi-asserted-by":"crossref","first-page":"144992","DOI":"10.1016\/j.gene.2020.144992","article-title":"Silencing circ_0001879 inhibits the proliferation and migration of human retinal microvascular endothelial cells under high-glucose conditions via modulating miR-30-3p","volume":"760","author":"Zeng","year":"2020","journal-title":"Gene"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib135","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0735-1097(99)00630-0","article-title":"Cardiac remodeling: concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling","volume":"35","author":"Cohn","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.gendis.2023.101174_bib136","doi-asserted-by":"crossref","first-page":"1215802","DOI":"10.1155\/2020\/1215802","article-title":"Adverse cardiac remodelling after acute myocardial infarction: old and new biomarkers","volume":"2020","author":"Berezin","year":"2020","journal-title":"Dis Markers"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib137","first-page":"62","article-title":"Cardiac remodeling: concepts, clinical impact, pathophysiological mechanisms and pharmacologic treatment","volume":"106","author":"Azevedo","year":"2016","journal-title":"Arq Bras Cardiol"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib138","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.113.001878","article-title":"Pathological ventricular remodeling: mechanisms: part 1 of 2","volume":"128","author":"Burchfield","year":"2013","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib139","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.gendis.2023.101174_bib140","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.gendis.2023.101174_bib141","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.gendis.2023.101174_bib142","first-page":"1164","article-title":"Empagliflozin reduces myocardial extracellular volume in patients with type 2 diabetes and coronary artery disease","volume":"14","author":"Mason","year":"2021","journal-title":"JACC"},{"issue":"12","key":"10.1016\/j.gendis.2023.101174_bib143","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.2337\/dc16-1312","article-title":"Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.gendis.2023.101174_bib144","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2022.05.010","article-title":"Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial","volume":"253","author":"Harrington","year":"2022","journal-title":"Am Heart J"},{"issue":"16","key":"10.1016\/j.gendis.2023.101174_bib145","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1111\/jcmm.16601","article-title":"Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats","volume":"25","author":"Tian","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"5","key":"10.1016\/j.gendis.2023.101174_bib146","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ajh\/hpz016","article-title":"Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload","volume":"32","author":"Shi","year":"2019","journal-title":"Am J Hypertens"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib147","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cjca.2019.08.033","article-title":"Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results","volume":"36","author":"Kang","year":"2020","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib148","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12933-016-0489-z","article-title":"Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes","volume":"16","author":"Habibi","year":"2017","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.gendis.2023.101174_bib149","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib150","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-016-0473-7","article-title":"Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome","volume":"15","author":"Kusaka","year":"2016","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"10.1016\/j.gendis.2023.101174_bib151","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1038\/s41401-022-00885-8","article-title":"Direct cardio-protection of dapagliflozin against obesity-related cardiomyopathy via NHE1\/MAPK signaling","volume":"43","author":"Lin","year":"2022","journal-title":"Acta Pharmacol Sin"},{"issue":"5","key":"10.1016\/j.gendis.2023.101174_bib152","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s13238-020-00809-4","article-title":"Cardioprotective mechanism of SGLT2 inhibitor against myocardial infarction is through reduction of autosis","volume":"13","author":"Jiang","year":"2022","journal-title":"Protein Cell"},{"issue":"7","key":"10.1016\/j.gendis.2023.101174_bib153","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1161\/01.RES.0000014966.97486.C0","article-title":"Inhibition of Na+-H+ exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice","volume":"90","author":"Engelhardt","year":"2002","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.gendis.2023.101174_bib154","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"issue":"14","key":"10.1016\/j.gendis.2023.101174_bib155","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1093\/cvr\/cvaa323","article-title":"Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+\/H+ exchanger-1 or lower[Na+]i in the heart","volume":"117","author":"Chung","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.gendis.2023.101174_bib156","doi-asserted-by":"crossref","first-page":"104781","DOI":"10.1016\/j.phrs.2020.104781","article-title":"Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium","volume":"157","author":"Cappetta","year":"2020","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.gendis.2023.101174_bib157","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib158","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12933-019-0964-4","article-title":"Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet\/streptozotocin-induced diabetic rats","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib159","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3390\/ijms23010437","article-title":"Attenuation of adverse postinfarction left ventricular remodeling with empagliflozin enhances mitochondria-linked cellular energetics and mitochondrial biogenesis","volume":"23","author":"Song","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.gendis.2023.101174_bib160","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1152\/physiolgenomics.00163.2011","article-title":"Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure","volume":"44","author":"Reddy","year":"2012","journal-title":"Physiol Genomics"},{"issue":"10","key":"10.1016\/j.gendis.2023.101174_bib161","doi-asserted-by":"crossref","first-page":"138027","DOI":"10.1172\/jci.insight.138027","article-title":"microRNA-30 regulates left ventricular hypertrophy in chronic kidney disease","volume":"6","author":"Bao","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.gendis.2023.101174_bib162","doi-asserted-by":"crossref","first-page":"104108","DOI":"10.1016\/j.ebiom.2022.104108","article-title":"Targeting miR-30d reverses pathological cardiac hypertrophy","volume":"81","author":"Li","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.gendis.2023.101174_bib163","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12967-015-0725-4","article-title":"microRNA regulation of unfolded protein response transcription factor XBP1 in the progression of cardiac hypertrophy and heart failure in vivo","volume":"13","author":"Duan","year":"2015","journal-title":"J Transl Med"},{"issue":"2","key":"10.1016\/j.gendis.2023.101174_bib164","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1074\/jbc.M112.412783","article-title":"XBP1 mRNA splicing triggers an autophagic response in endothelial cells through BECLIN-1 transcriptional activation","volume":"288","author":"Margariti","year":"2013","journal-title":"J Biol Chem"},{"issue":"11","key":"10.1016\/j.gendis.2023.101174_bib165","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1210\/en.2014-1106","article-title":"Triiodothyronine prevents cardiac ischemia\/reperfusion mitochondrial impairment and cell loss by regulating miR30a\/p53 axis","volume":"155","author":"Forini","year":"2014","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.gendis.2023.101174_bib166","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/4050116d-8daa-4b5a-99e9-34cdd13f6a26","article-title":"miR-30 regulates mitochondrial fission through targeting p53 and the dynamin-related protein-1 pathway","volume":"6","author":"Li","year":"2010","journal-title":"PLoS Genet"},{"issue":"4","key":"10.1016\/j.gendis.2023.101174_bib167","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10741-016-9554-7","article-title":"Thyroid hormones and cardiac remodeling","volume":"21","author":"Cokkinos","year":"2016","journal-title":"Heart Fail Rev"},{"issue":"10","key":"10.1016\/j.gendis.2023.101174_bib168","doi-asserted-by":"crossref","first-page":"17326","DOI":"10.1002\/jcb.28996","article-title":"miRNA-30-3p improves myocardial ischemia via the PTEN\/PI3K\/AKT signaling pathway","volume":"120","author":"Yin","year":"2019","journal-title":"J Cell Biochem"}],"container-title":["Genes & Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304223004579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304223004579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,15]],"date-time":"2024-09-15T11:37:56Z","timestamp":1726400276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304223004579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":168,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2352304223004579"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2023.101174","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2023.101174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101174"}}